Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Aug 12, 2022 11:02am
214 Views
Post# 34891503

RE:Pancreatic cancer data a game changer for this stock

RE:Pancreatic cancer data a game changer for this stockI agree, the Panc cancer ( goblet with Roche), is a game changer.
In my 20+ yrs of following Onc, this has been the most positive outcome.
I strongly recommend everyone, new old or just thinking about owning Onc shares, log into 
oncolytics biotech & listen to the conference call.
first time ever, that I can recall...the B.D. Guy acknowledged they have had multiple offers, yet are waiting for a more favourable deal.
At the 19:20 time or so, they discuss multiple discussions with multiple potential partners , something like that.
most importantly, they were extremely clear. If the remaining panc resukts are as good as the first, they will be Persuing a second phase 3 trial.
THAT data etc will be public before the end of this year.
please don't take my word. Go & listen,.
or on Alpha trader, there is a published transcript.

<< Previous
Bullboard Posts
Next >>